Peer-reviewed veterinary case report
15-week CHOP chemo for dogs with multicentric lymphoma results
By Curran, K. & Thamm, D. H.·Published in Veterinary and Comparative Oncology·2015·Flint Animal Cancer Center Colorado State University Fort Collins CO USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15‐week, maintenance‐freeCHOPprotocol
- Species:
- dog
Plain-English summary
A group of 134 dogs with multicentric lymphoma (a type of cancer) underwent a 15-week chemotherapy treatment using a combination of drugs known as CHOP. This shorter treatment plan had a very high success rate, with 98% of the dogs responding positively, and 104 dogs achieving complete remission. On average, dogs lived about 311 days after starting treatment, with many experiencing a good quality of life during that time. This approach may be a good option for pet owners who are concerned about the length and intensity of traditional chemotherapy protocols.
People also search for: dog lymphoma treatment · canine cancer chemotherapy · multicentric lymphoma prognosis · dog cancer survival rates · CHOP protocol for dogs
Abstract
AbstractStandard of care treatment of dogs with multicentric lymphoma includes combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); however, owners may be hesitant to commit the resources necessary to complete a lengthy, multi‐drug protocol. One hundred thirty‐four client‐owned dogs with multicentric lymphoma were treated with a 15‐weekCHOPchemotherapy protocol. The overall response rate was 98% with 104 dogs experiencing a complete response (CR). The median progression‐free survival (PFS) time for all dogs was 176 days, and the median disease‐specific overall survival time was 311 days. Prognostic factors identified on multivariate analysis as significant forPFSincluded substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing aCRas best response to therapy. In conclusion, this protocol may be a viable alternative toCHOPprotocols using a larger number of treatments.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12163